









Markets
/
Stocks
/
nasdaq-omer
/

Omeros Corp

OMER

4.260USD

+0.200+4.93%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

255.70MMarket Cap

LossP/E TTM



Omeros Corp

4.260

+0.200+4.93%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

149 / 507

Overall Ranking

277 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

30.000

Target Price

+644.42%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Undervalued

The company’s latest PE is -1.93, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 30.16M shares, decreasing 1.38% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.28M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 6.00, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.00

Change



Financials

5.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.93, which is -299.25% below the recent high of 3.84 and 0.76% above the recent low of -1.91.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 149/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 7.60, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Omeros Corp is 36.00, with a high of 45.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

30.000

Target Price

+638.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Omeros Corp

OMER

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.70, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 4.45 and the support level at 3.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.30

Change

0.4

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.084

Neutral

RSI(14)

46.518

Neutral

STOCH(KDJ)(9,3,3)

21.292

Neutral

ATR(14)

0.170

High Vlolatility

CCI(14)

-140.668

Sell

Williams %R

75.758

Sell

TRIX(12,20)

0.081

Sell

StochRSI(14)

20.993

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.106

Buy

MA10

4.162

Buy

MA20

4.227

Buy

MA50

4.002

Buy

MA100

4.065

Buy

MA200

6.435

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 44.94%, representing a quarter-over-quarter decrease of 13.41%. The largest institutional shareholder is The Vanguard, holding a total of 3.28M shares, representing 4.82% of shares outstanding, with 11.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Ingalls & Snyder LLC (Asset Management)

3.98M

-0.75%

BlackRock Institutional Trust Company, N.A.

4.02M

+1.47%

The Vanguard Group, Inc.

Star Investors

3.24M

+3.04%

Demopulos (Gregory A. M.D.)

2.03M

D. E. Shaw & Co., L.P.

1.94M

+5.42%

Stifel, Nicolaus & Company, Incorporated

1.56M

-1.55%

Geode Capital Management, L.L.C.

1.37M

+2.22%

State Street Global Advisors (US)

1.36M

+11.93%

Morgan Stanley & Co. LLC

584.71K

+180.19%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.